Purpose

This pilot study is a prospective, randomized clinical trial to evaluate the effect of anesthesia in the mitochondrial dysfunction patient.

Condition

Eligibility

Eligible Ages
Between 1 Day and 17 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subjects must fulfill the following inclusion criteria: - Subject is informed and given ample opportunity to consider his/her participation and has given his/her written consent. - Subject is willing and able to comply with all study requirements. - Subject is between 0 - 17 years of age. - Subject has been diagnosed with mitochondrial dysfunction based on modified Walker criteria. - Subject is scheduled to have a non-emergent diagnostic or therapeutic procedure for routine medical care requiring general anesthesia estimated to last at least one hour. - Subject is classified ASA I - IV

Exclusion Criteria

Subjects are not permitted to enroll in the study if any of the following criteria are met: - Subject is older than 17 years - Subject is pregnant - Subject is a nursing female and - Subject has participated in the same study within 48 hours - Subject is allergic or has had any adverse effect to any of the study agents in the past - Anesthesia time is less than one hour - Subject is classified ASA V

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Other
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Sevoflurane
In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
  • Drug: Sevoflurane
    Sevoflurane up to 8% will be administered to study subjects
    Other names:
    • Ultane
Active Comparator
Dexmedetomidine (Precedex®)
These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
  • Drug: Dexmedetomidine
    Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
    Other names:
    • Precedex
Active Comparator
Propofol
These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
  • Drug: Propofol
    Propofol up to 50 mcg/ kg/min will be administered to study subjects.
    Other names:
    • Diprivan

Recruiting Locations

University of Texas Health Science Center at Houston
Houston, Texas 77030
Contact:
Stephanie Maldonado
713-828-4291
Stephanie.Maldonado@uth.tmc.edu

More Details

Status
Unknown status
Sponsor
The University of Texas Health Science Center, Houston

Study Contact

Stephanie Maldonado
713-828-4291
Stephanie.Maldonado@uth.tmc.edu

Detailed Description

Study subjects undergoing a routine medical care non-emergent procedure will be randomized into three different groups to receive one of the following anesthetic agents; Sevoflurane, Propofol or Dexmedetomidine. The primary outcome of this pilot study is to evaluate and compare the incidence of adverse events in mitochondrial patients undergoing a diagnostic or therapeutic procedure up to 48 hours post anesthesia. The secondary outcome is to compare the metabolic derangements between three study groups by comparing changes in blood sugar, serum pH, serum bicarbonate, serum lactate and serum pyruvate levels before, during and after anesthesia in the groups.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.